fd618c1b-e230-408d-aed8-4ad6df3fc4e6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.550
- ALLOGRAFT_REJECTION+0.430
- INFLAMMATORY_RESPONSE+0.430
- COAGULATION+0.400
- COMPLEMENT+0.400
- KRAS_SIGNALING_UP+0.390
- UV_RESPONSE_DN+0.370
- IL2_STAT5_SIGNALING+0.350
- IL6_JAK_STAT3_SIGNALING+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- MYC_TARGETS_V1-0.520
- OXIDATIVE_PHOSPHORYLATION-0.430
- DNA_REPAIR-0.390
- E2F_TARGETS-0.370
- G2M_CHECKPOINT-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.290
- ESTROGEN_RESPONSE_LATE-0.250
- PEROXISOME-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 07234abb-aa8c-434f-898c-6f7ba28c5850 | — | — | 0.941 |
| 2 | TCGA-A2-A0T6-01A-11R-A084-07 | — | A | 0.933 |
| 3 | 69842b4c-448a-4275-8250-7b31948c56ec | — | — | 0.928 |
| 4 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.928 |
| 5 | SRR8518425 | — | A | 0.922 |
| 6 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.922 |
| 7 | TCGA-CN-4728-01A-01R-1436-07 | — | — | 0.919 |
| 8 | C3N-02923 | — | cohortMD2 | 0.917 |
| 9 | SRR35579817 | — | A | 0.915 |
| 10 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |